

# Odelia Cooper

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/457370/publications.pdf>

Version: 2024-02-01

34  
papers

1,708  
citations

304743

22  
h-index

477307

29  
g-index

35  
all docs

35  
docs citations

35  
times ranked

1773  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dural Invasion as a Marker of Aggressive Pituitary Adenomas. <i>Neurosurgery</i> , 2022, 90, 775-783.	1.1	3
2	EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e917-e925.	3.6	37
3	Pembrolizumab-Induced Diabetic Ketoacidosis: A Review of Critical Care Case. <i>Cureus</i> , 2021, 13, e18983.	0.5	3
4	Treatment of Aggressive Pituitary Adenomas: A Case-Based Narrative Review. <i>Frontiers in Endocrinology</i> , 2021, 12, 725014.	3.5	6
5	Editorial: Targeted Therapy for Pituitary Adenomas. <i>Frontiers in Endocrinology</i> , 2019, 10, 358.	3.5	3
6	SUN-442 EGFR/ErbB2 Targeted Therapy for Aggressive Prolactinomas. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	8
7	SUN-461 Predictors of Early and Late Hyponatremia after Pituitary Surgery. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	0
8	Silent corticotroph adenomas. <i>Pituitary</i> , 2018, 21, 183-193.	2.9	87
9	Dopamine Agonists for Pituitary Adenomas. <i>Frontiers in Endocrinology</i> , 2018, 9, 469.	3.5	33
10	Sellar and clival plasmacytomas: case series of 5 patients with systematic review of 65 published cases. <i>Pituitary</i> , 2017, 20, 381-392.	2.9	23
11	Long-Term Endocrine Outcomes Following Endoscopic Endonasal Transsphenoidal Surgery for Acromegaly and Associated Prognostic Factors. <i>Neurosurgery</i> , 2017, 81, 357-366.	1.1	67
12	Role of tyrosine kinase inhibitors in the treatment of pituitary tumours. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2017, 24, 301-305.	2.3	33
13	Altered Pituitary Gland Structure and Function in Posttraumatic Stress Disorder. <i>Journal of the Endocrine Society</i> , 2017, 1, 577-587.	0.2	15
14	A Structural and Functional Acromegaly Classification. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 122-131.	3.6	97
15	Silent corticotroph adenomas. <i>Pituitary</i> , 2015, 18, 225-231.	2.9	58
16	ErbB Receptor-Driven Prolactinomas Respond to Targeted Lapatinib Treatment in Female Transgenic Mice. <i>Endocrinology</i> , 2015, 156, 71-79.	2.8	33
17	Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors. <i>Endocrine</i> , 2014, 46, 318-327.	2.3	69
18	Single-surgeon fully endoscopic endonasal transsphenoidal surgery: outcomes in three-hundred consecutive cases. <i>Pituitary</i> , 2013, 16, 393-401.	2.9	79

#	ARTICLE	IF	CITATIONS
19	Bisphosphonate Drug Holiday: Choosing Appropriate Candidates. <i>Current Osteoporosis Reports</i> , 2013, 11, 45-51.	3.6	30
20	Ectopic acromegaly due to growth hormone releasing hormone. <i>Endocrine</i> , 2013, 43, 293-302.	2.3	58
21	Hypertension Therapy. , 2013, , 561-575.		0
22	Subclinical hyperfunctioning pituitary adenomas: The silent tumors. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2012, 26, 447-460.	4.7	70
23	EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. <i>Journal of Clinical Investigation</i> , 2011, 121, 4712-4721.	8.2	220
24	Expression and function of ErbB receptors and ligands in the pituitary. <i>Endocrine-Related Cancer</i> , 2011, 18, R197-R211.	3.1	61
25	HER2/ErbB2 Receptor Signaling in Rat and Human Prolactinoma Cells: Strategy for Targeted Prolactinoma Therapy. <i>Molecular Endocrinology</i> , 2011, 25, 92-103.	3.7	64
26	HER2/ErbB2 Receptor Signaling in Rat and Human Prolactinoma Cells: Strategy for Targeted Prolactinoma Therapy. <i>Endocrine Reviews</i> , 2010, 31, 943-943.	20.1	0
27	Silent Corticogonadotroph Adenomas: Clinical and Cellular Characteristics and Long-Term Outcomes. <i>Hormones and Cancer</i> , 2010, 1, 80-92.	4.9	72
28	HER2/ErbB2 Receptor Signaling in Rat and Human Prolactinoma Cells: Strategy for Targeted Prolactinoma Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 5457-5457.	3.6	0
29	Heregulin Regulates Prolactinoma Gene Expression. <i>Cancer Research</i> , 2009, 69, 4209-4216.	0.9	35
30	Ovarian hyperstimulation syndrome caused by an FSH-secreting pituitary adenoma. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008, 4, 234-238.	2.8	43
31	Opiate Drug Use: A Potential Contributor to the Endocrine and Metabolic Complications in Human Immunodeficiency Virus Disease. <i>Clinical Infectious Diseases</i> , 2003, 37, S132-S136.	5.8	66
32	D-aspartate localizations imply neuronal and neuroendocrine roles. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 2013-2018.	7.1	206
33	Human and murine pituitary expression of leukemia inhibitory factor. Novel intrapituitary regulation of adrenocorticotropin hormone synthesis and secretion.. <i>Journal of Clinical Investigation</i> , 1995, 95, 1288-1298.	8.2	129
34	Cabergoline is an effective treatment for clinically non-functioning pituitary adenomas. <i>Endocrine Abstracts</i> , 0, , .	0.0	0